What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Guselkumab has demonstrated moderate clinical effectiveness, showing superiority over placebo in clinical trials. However, it has not been directly compared to other treatments like mirikizumab or vedolizumab, which limits the strength of the evidence. The indirect comparisons suggest it is likely to be as effective as these alternatives, but the lack of direct evidence prevents a higher rating.
Does the economic case hold at the expected price? — Cost effectiveness
Guselkumab is considered cost-effective compared to other treatments, with a cost comparison suggesting similar or lower costs than mirikizumab and vedolizumab. This aligns with common thresholds for cost-effectiveness, indicating a strong value proposition.
Is there quality-of-life evidence payers weigh? — Quality of life
The evidence indicates that guselkumab provides moderate improvements in health-related quality of life for patients with ulcerative colitis, although specific validated tools and effect sizes are not detailed in the document. The overall positive impact on patient well-being supports this rating.
Does the safety profile hold up for payers? — Safety and Adverse Effects
The safety profile of guselkumab is reported to be very good, with mostly mild or moderate adverse events. There are no significant safety concerns raised in the document, supporting a favorable rating.
Was the drug compared against what payers expect? — Comparator Selection
While guselkumab has been compared to placebo, the lack of direct head-to-head trials against key comparators like mirikizumab and vedolizumab raises concerns. The indirect comparisons used are acceptable but do not provide the robustness of direct evidence.
Is the population defined the way payers need it? — Patient Population and Subgroups
The patient population for guselkumab is well-defined, targeting adults with moderately to severely active ulcerative colitis who have not responded to other treatments. This specificity supports a moderate to high rating for representativeness.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Guselkumab can be integrated into existing treatment pathways with minor adjustments, as it is used after other treatments have failed. This indicates a good fit within current clinical practices.
Are the wider system costs understood? — Resource Use and Cost Implications
The budget impact of guselkumab is manageable, with the document indicating that it is aligned with planning and does not present a significant financial burden on the healthcare system.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence supporting guselkumab is derived from clinical trials with a good design, although there are some limitations due to the absence of direct comparisons with all relevant alternatives. Overall, the evidence is credible and robust.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There is manageable uncertainty regarding the effectiveness of guselkumab, particularly due to the indirect comparisons. However, the context of unmet need in ulcerative colitis supports a favorable assessment.
